title: A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
abstract: OBJECTIVE
  Comparing antiemetic efficacy of different 5-HT(3)-receptor antagonists (5-HT(3)RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV).
  
  
  METHODS
  Comparisons between 5-HT(3)RAs were based on 44 randomized studies (including 12,343 patients) identified by MEDLINE, CANCERLIT or EMBASE searches and subcategorized by chemotherapy type (cisplatin- or non-cisplatin-based).
  
  
  RESULTS
  When all studies were combined, granisetron was equivalent to ondansetron (n = 27), and showed an advantage vs tropisetron (p = 0.018; n = 12). Ondansetron vs tropisetron (n = 11) and ondansetron vs dolasetron (n = 3) revealed equivalence in each comparison. An advantage for 3 mg granisetron vs 8 mg ondansetron was found in non-cisplatin-based studies (p = 0.015; n = 6). Overall equivalence was seen between ondansetron, 24 or 32 mg, and granisetron, 2 or 3 mg, for all studies (n = 13). There was a possible advantage for higher (24 or 32 mg) vs lower (8 mg) ondansetron dose regimens with cisplatin-based trials (n = 6). No differences were seen between 3 and 1 mg granisetron doses (n = 6).
  
  
  CONCLUSIONS
  Efficacy of 5-HT(3)RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.
authors.affiliation: Department for Hematology/Oncology, Martin-Luther University Halle/Wittenberg, Ernst-Grube-Str. 40, 06120 Halle, Germany. karin.jordan@medizin.uni-halle.de
authors.forename: K
authors.initials: K
authors.lastname: Jordan
authors.forename: A
authors.initials: A
authors.lastname: Hinke
authors.forename: A
authors.initials: A
authors.lastname: Grothey
authors.forename: W
authors.initials: W
authors.lastname: Voigt
authors.forename: D
authors.initials: D
authors.lastname: Arnold
authors.forename: H-H
authors.initials: HH
authors.lastname: Wolf
authors.forename: H-J
authors.initials: HJ
authors.lastname: Schmoll
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017829:Granisetron / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D017294:Ondansetron / Q000627:therapeutic use; D011807:Quinolizines / Q000627:therapeutic use; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D016896:Treatment Outcome; D000077526:Tropisetron; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D017829:Granisetron; D007211:Indoles; D017294:Ondansetron; D011807:Quinolizines; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists; D000077526:Tropisetron; C060344:dolasetron